Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028653 | 0.82 | CA2 (0.50) | TDP1CA1CA2CA9APLNR | |
| SCHEMBL20401438 | 0.82 | ALDH1A1 (0.38) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL31018073 | 0.79 | ALDH1A1 (0.56) | ALDH1A1NPSR1HSD17B10TDP1CA1 | |
| SCHEMBL958949 | 0.79 | ALDH1A1 (0.56) | ALDH1A1NPSR1HSD17B10TDP1CA1 | |
| SCHEMBL21633518 | 0.78 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL1040704 | 0.76 | ALDH1A1 (0.38) | ALDH1A1NPSR1HSD17B10TDP1CA1 | |
| SCHEMBL20656381 | 0.76 | ALDH1A1 (0.38) | ALDH1A1NPSR1HSD17B10TDP1CA1 | |
| SCHEMBL16235478 | 0.76 | ALDH1A1 (0.41) | ALDH1A1NPSR1HSD17B10TDP1CA1 | |
| SCHEMBL31294199 | 0.74 | HTT (0.42) | ALDH1A1NPSR1MAPTTP53MEN1 | |
| SCHEMBL20656519 | 0.72 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096637-A1 | SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2025-05-08 | — | — | WO | disclosed |
| CN-112638879-B | Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-112638898-B | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-20220348570-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2022-11-03 | — | — | US | disclosed |
| EP-3844150-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2021-07-07 | — | — | EP | disclosed |
| EP-3844158-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | Xenon Pharmaceuticals Inc. (CA) | 2021-07-07 | — | — | EP | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047312-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047312-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | ALDH1A1 3021/4885NPSR1 471/4885HSD17B10 1566/4885 |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | ALDH1A1 2781/4885NPSR1 455/4885HSD17B10 2086/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | ALDH1A1 3021/4885NPSR1 471/4885HSD17B10 1566/4885 |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | ALDH1A1 2781/4885NPSR1 455/4885HSD17B10 2086/4885 |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | ALDH1A1 2781/4885NPSR1 455/4885HSD17B10 2086/4885 |
| US-20220348570-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | ALDH1A1 2781/4885NPSR1 455/4885HSD17B10 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.